

Preparing for the Gene & Cell Therapy Wave


Stephen Majors, Director of Public Affairs

PartnerRe Webinar March 10, 2021

© 2021 Alliance for Regenerative Medicine

ARM is the Global Voice of the Sector *Representing* 380+ *members worldwide*

Patient Organizations



Promote Clear Regulation Enable Innovative Reimbursement Address Manufacturing Barriers Educate Stakeholders

How is Regenerative Medicine Different?

Conventional Chronic Care Therapy

Addresses: Symptoms of diseases

Dosage: May be administered regularly over patient's lifetime

Cost: Throughout a patient's lifetime

.....

.....

Outcomes: Last for short periods; repeated dosing needed

Regenerative Medicine

Addresses: Root cause of diseases

Dosage: Potentially curative, single or

........


very limited number of injections

.

Cost : Largely upfront, packed into a small number of doses or a single dose

Outcomes: Last for long periods, possibly for a lifetime

........



Examples of Regenerative Medicine



Gene Therapy

Introduces a functioning gene into a patient's cells

One approved durable therapy for 'SMA1', a devastating genetic disorder that kills 90% of children who have it before their second birthday



Gene Editing

Inserts, replaces, removes or modifies DNA

Shows promise in clinical trials to durably treat or cure diseases including sicklecell, which affects 1 in every 365 Black babies born in the US



Cell Therapy

Transfers cells into a patient to treat disease

4 approved therapies to treat leukemias and lymphomas that are unresponsive to other treatments




Tissue-Based Therapy

Replaces damaged tissue with natural or synthetic tissue

Currently approved products can treat severe burns and wounds; may also be used to repair or replaced damaged organs





\$19.9B raised in 2020

Shattering previous annual financing records

\$9.8B RAISED IN 2019

\$13.3B RAISED IN 2018

\$7.5B RAISED IN 2017

Data by 🔘 GlobalData.

© 2021 Alliance for Regenerative Medicine

1,085


TOTAL GENE, CELL & TISSUE-BASED THERAPEUTIC DEVELOPERS WORLDWIDE




Recent Approvals:

- Breyanzi® (Bristol Myers Squibb) US
- Tecartus® (Kite, a Gilead company) US
- Libmeldy® (Orchard Tx) Europe
- Zolgensma® (Novartis Gene Therapies) Europe, Japan, Canada
- Luxturna® (Spark / Roche) Canada





8 © 2021 Alliance for Regenerative Medicine Data by 🚫 GlobalData.



1,**220** ONGOING REGENERATIVE MEDICINE & ADVANCED THERAPY TRIALS WORLDWIDE


419 in cell-based IO

Data by 🚫 GlobalData.

9

© 2021 Alliance for Regenerative Medicine

Clinical Trials by Indication



10 © 2021 Alliance for Regenerative Medicine





The Scientific and Clinical Landscape

Integrating cutting edge technologies A broader range of cell types New milestones for allogeneic therapies Breaking into the solid tumor space



A Challenging Environment

COVID-driven operational and clinical disruptions


Pandemic limited regulators' CGT bandwidth and travel

The politicization of COVID vaccines

Growing industry demands and fast-moving science



The Coming Wave of Cell & Gene Therapies: Patient Impact



By 2030, more than 500,000 Americans could receive a regenerative medicine product

The FDA is expected to decide on:

- Stratagraft[®], a tissue engineered product to treat severe burns (April)
- Ide-cel® (March) & cilta-cel® (late 2021 / early 2022), CAR-T therapies for multiple myeloma





Regenerative Medicine & Multiple Myeloma



Standard of Care

35k patients diagnosed with multiple myeloma in the U.S. annually

5-year mean survival from diagnosis

Annual healthcare costs: \$280,000 per patient


The Multiple Myeloma Pipeline

117 Developers Active in Multiple Myeloma


186 Regenerative Medicine Therapies in Development

74 Clinical Stage Therapies





Cost Savings from a Durable Multiple Myeloma Treatment




Patient Outcomes

Clinical trials demonstrate deep & durable responses with 12+ months of follow-up

Ide-cel® bluebird bio, BMS

> *Under standard of care, most patients with relapsed / refractory multiple myeloma die within 6 months*



Cilta-cel® Janssen, Legend





THE UNIVERSITY OF TEXAS MDAnderson Cancer Center

Multiple myeloma survivor grateful CAR T cell therapy clinical trial gives her another option



From publicly available information



www.alliancerm.org

